2022 Top 500 ranking: 42
A lack of research and development into new antibiotic classes compounds the serious threat that antimicrobial resistance poses to public health. In the fifth article in our pandemic series, Kimberley Lewis explores the role of pharmaceutical companies and how we engage on this key topic.
Non-asset management investment service providers are able to purchase a subscription for access to premium content such as:
Get access to premium content subscribe today